Promethazine during pregnancy for hemolytic disease of the newborn
Bergman, A.; Yedwab, G.A.; Avni, A.; David, M.P.
Harefuah 102(6): 221-223
1982
ISSN/ISBN: 0017-7768 PMID: 7160713 Document Number: 188225
Promethazine hydrochloride was administered to 4 pregnant women known to be sensitized as a result of Rh incompatibility. It was administered throughout pregnancy, 300 mg/day. Severity of the hemolytic disease was checked by repeated amniocenteses until delivery. Criteria of successful treatment were hemolytic disease of the newborn less severe than in the previous pregnancy and no case of hydrops fetalis. Promethazine hydrochloride is believed to diminish the severity of the hemolytic disease by reducing fetal erythrocyte destruction through its immunosuppressive effect. The drug was well tolerated by the pregnant women at the dosage used and severe side effects when administered during pregnancy have not been reported.